Endogenously, GLP-1 is secreted by intestinal L cells in response to food, and has multiple roles: enhancing insulin secretion (in a glucose-dependent way), reducing glucagon secretion, slowing gastric emptying, increasing feelings of fullness/satiety, and improving glucose disposal in peripheral tissues

Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
How postbiotics may support GLP-1 Your gut microbiome influences GLP-1 production through several mechanisms
She said BMI alone is insufficient to assess risk and waist circumference should also be taken into account
January 14, 2026
There is also some data to suggest that GLP-1 may improve the gut microbiome to a pattern that is more favourable to weight loss